GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:05 2024-04-15 am EDT 5-day change 1st Jan Change
1,644 GBX 0.00% Intraday chart for GSK plc +1.45% +13.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pfizer RSV shot meets goals in trial of high-risk adults under age 60 RE
GSK : Barclays sticks Neutral ZD
Barclays Lifts GSK PT, Maintains Equalweight Rating MT
Wizz Air raised; HSBC cuts Rentokil to 'hold' AN
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers MT
GSK : Barclays reiterates its Neutral rating ZD
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study MT
Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs RE
GSK : Berenberg gives a Buy rating ZD
GSK : Sell rating from JP Morgan ZD
U.S. FDA approves Akebia's anemia drug RE
GSK FILES FOR DEBT SHELF; SIZE NOT DISCLOSED - SEC FILING… RE
Moderna, Inc. prepares for the post-Covid era Our Logo
British Drugmaker GSK to Introduce Price Cap on Inhaled Products from 2025 MT
GSK to cap out-of-pocket inhaler costs in US RE
GSK Announces Cap Of $35 Per Month On U.S. Patient Out-Of-Pocket Costs RE
GSK - PROGRAM IS WIDE REACHING AND WILL BE IMPLEMENTED NO LATER… RE
GSK ANNOUNCES CAP OF $35 PER MONTH ON U.S. PATIENT OUT-OF-POCKET… RE
GSK : Buy rating from Jefferies ZD
CAC40: Paris and E-Stoxx50 close at record highs CF
Repeat & Correct : Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale -- Update DJ
CAC40: in record territory, oil at year's high CF
GSK : UBS reaffirms its Buy rating ZD
UBS Keeps GSK at Buy, Lifts PT MT
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.44 GBP
Average target price
20 GBP
Spread / Average Target
+21.69%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. ViiV Says Trial Data Shows Injectable HIV Treatment Cabenuva Has 'Superior Efficacy' Compared With Pills in Some People